KR102035882B1 - 브라디키닌 b1 수용체 리간드에 대한 항체 - Google Patents

브라디키닌 b1 수용체 리간드에 대한 항체 Download PDF

Info

Publication number
KR102035882B1
KR102035882B1 KR1020147029192A KR20147029192A KR102035882B1 KR 102035882 B1 KR102035882 B1 KR 102035882B1 KR 1020147029192 A KR1020147029192 A KR 1020147029192A KR 20147029192 A KR20147029192 A KR 20147029192A KR 102035882 B1 KR102035882 B1 KR 102035882B1
Authority
KR
South Korea
Prior art keywords
des
seq
antibody
calidine
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147029192A
Other languages
English (en)
Korean (ko)
Other versions
KR20150002679A (ko
Inventor
한 리
도로씨아 코미노스
지에 장
알라 프리츠커
매튜 데이비슨
니콜라 보랭
고빈단 서브라마니안
신 첸
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102035882(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피 filed Critical 사노피
Publication of KR20150002679A publication Critical patent/KR20150002679A/ko
Application granted granted Critical
Publication of KR102035882B1 publication Critical patent/KR102035882B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147029192A 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체 Active KR102035882B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
US61/616,845 2012-03-28
FR1350953 2013-02-04
FR1350953 2013-02-04
PCT/US2013/031836 WO2013148296A1 (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030406A Division KR102166083B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Publications (2)

Publication Number Publication Date
KR20150002679A KR20150002679A (ko) 2015-01-07
KR102035882B1 true KR102035882B1 (ko) 2019-10-24

Family

ID=49261064

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020147029192A Active KR102035882B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020207028912A Active KR102367723B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020197030406A Active KR102166083B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020227005891A Ceased KR20220031728A (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207028912A Active KR102367723B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020197030406A Active KR102166083B1 (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체
KR1020227005891A Ceased KR20220031728A (ko) 2012-03-28 2013-03-15 브라디키닌 b1 수용체 리간드에 대한 항체

Country Status (38)

Country Link
US (5) US9376494B2 (enExample)
EP (2) EP2831113B1 (enExample)
JP (5) JP6779012B2 (enExample)
KR (4) KR102035882B1 (enExample)
CN (3) CN120441698A (enExample)
AR (1) AR090352A1 (enExample)
AU (2) AU2013240242B2 (enExample)
BR (1) BR112014024282A2 (enExample)
CA (1) CA2868353C (enExample)
CL (2) CL2014002590A1 (enExample)
CO (1) CO7111293A2 (enExample)
CR (1) CR20140440A (enExample)
CY (1) CY1121466T1 (enExample)
DK (2) DK3246339T3 (enExample)
DO (1) DOP2014000199A (enExample)
EA (1) EA201491784A1 (enExample)
ES (1) ES2673869T3 (enExample)
GT (1) GT201400192A (enExample)
HR (1) HRP20180928T1 (enExample)
HU (1) HUE037720T2 (enExample)
IL (1) IL234830B (enExample)
LT (1) LT2831113T (enExample)
MA (1) MA37407B1 (enExample)
MX (2) MX361874B (enExample)
MY (2) MY184037A (enExample)
NZ (1) NZ631543A (enExample)
PE (1) PE20142170A1 (enExample)
PH (1) PH12014501970A1 (enExample)
PL (1) PL2831113T3 (enExample)
PT (1) PT2831113T (enExample)
RS (1) RS57413B1 (enExample)
SG (2) SG11201405162YA (enExample)
SI (1) SI2831113T1 (enExample)
TR (1) TR201808486T4 (enExample)
TW (1) TWI605060B (enExample)
UA (1) UA117097C2 (enExample)
UY (1) UY34682A (enExample)
WO (1) WO2013148296A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180928T1 (hr) * 2012-03-28 2018-07-27 Sanofi Protutijela za ligande bradikinin b1 receptora
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
CN118562001A (zh) * 2017-05-08 2024-08-30 阿迪马布有限责任公司 抗cd3结合结构域和包含它们的抗体以及它们的产生及使用方法
WO2019148186A1 (en) * 2018-01-29 2019-08-01 Silarus Therapeutics, Inc. Antibodies binding erfe and methods of use
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN119306824B (zh) * 2024-10-08 2025-09-26 江苏埃尔迪生物科技有限公司 一种全价展示scFv的通用型M13噬菌体探针及其构建方法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de) 1990-03-20 1997-10-15 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003209446B2 (en) 2002-03-01 2008-09-25 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2502904C (en) 2002-10-15 2013-05-28 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2005018572A2 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
DE602005015542D1 (de) 2004-01-12 2009-09-03 Applied Molecular Evolution Varianten der fc-region
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
MX2007015781A (es) 2005-06-14 2008-02-15 Cytos Biotechnology Ag Conjugados antigenos y sus usos.
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
EA200970477A1 (ru) * 2006-11-15 2009-12-30 Медарекс, Инк. Человеческие моноклональные антитела к btla и способы применения
WO2008151204A1 (en) 2007-06-04 2008-12-11 Sequent Medical Inc. Methods and devices for treatment of vascular defects
EP2170389B1 (en) * 2007-06-12 2014-10-29 AC Immune S.A. Humanized antibodies to amyloid beta
HUE037489T2 (hu) 2007-08-29 2018-08-28 Sanofi Sa Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk
CA2704583A1 (en) * 2007-11-07 2009-05-14 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 receptor(dec-205)
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
HRP20180928T1 (hr) * 2012-03-28 2018-07-27 Sanofi Protutijela za ligande bradikinin b1 receptora

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biochimia et Biophysica Acta, Vol 842, Pages 90-99(1985)*
Regulatory Peptide, Vol.33, pp.321-329(1991.)

Also Published As

Publication number Publication date
DK2831113T3 (en) 2018-06-25
CN120441698A (zh) 2025-08-08
CL2014002590A1 (es) 2015-01-16
MX2018015914A (es) 2021-12-08
BR112014024282A2 (pt) 2017-08-08
US20180222967A1 (en) 2018-08-09
PL2831113T3 (pl) 2018-08-31
WO2013148296A1 (en) 2013-10-03
RS57413B1 (sr) 2018-09-28
EP2831113B1 (en) 2018-03-14
US10465002B2 (en) 2019-11-05
CA2868353C (en) 2023-10-31
CO7111293A2 (es) 2014-11-10
KR102166083B1 (ko) 2020-10-16
HRP20180928T1 (hr) 2018-07-27
AU2018203081A1 (en) 2018-05-24
CN113773385B (zh) 2025-09-12
PE20142170A1 (es) 2015-01-07
EP2831113A1 (en) 2015-02-04
AU2013240242A1 (en) 2014-10-02
NZ631543A (en) 2017-03-31
SI2831113T1 (en) 2018-08-31
ES2673869T3 (es) 2018-06-26
CL2017003039A1 (es) 2018-03-16
IL234830B (en) 2018-11-29
HK1206754A1 (en) 2016-01-15
KR20150002679A (ko) 2015-01-07
MX361874B (es) 2018-12-18
EP3246339A1 (en) 2017-11-22
US9376494B2 (en) 2016-06-28
JP7411609B2 (ja) 2024-01-11
TWI605060B (zh) 2017-11-11
HUE037720T2 (hu) 2018-09-28
CN104334578A (zh) 2015-02-04
US20230399388A1 (en) 2023-12-14
SG10201702396QA (en) 2017-04-27
JP2015513903A (ja) 2015-05-18
UY34682A (es) 2013-10-31
TR201808486T4 (tr) 2018-07-23
AU2013240242B2 (en) 2018-02-08
CN113773385A (zh) 2021-12-10
KR102367723B1 (ko) 2022-02-28
GT201400192A (es) 2015-07-29
JP2025134874A (ja) 2025-09-17
KR20200121370A (ko) 2020-10-23
TW201343671A (zh) 2013-11-01
PH12014501970A1 (en) 2014-11-17
EP3246339B1 (en) 2019-10-09
US20150050270A1 (en) 2015-02-19
KR20220031728A (ko) 2022-03-11
US20200115441A1 (en) 2020-04-16
US9879079B2 (en) 2018-01-30
US20160368976A1 (en) 2016-12-22
AR090352A1 (es) 2014-11-05
LT2831113T (lt) 2018-06-25
JP2021166538A (ja) 2021-10-21
UA117097C2 (uk) 2018-06-25
JP6912441B2 (ja) 2021-08-04
CR20140440A (es) 2014-11-17
KR20190121861A (ko) 2019-10-28
SG11201405162YA (en) 2014-09-26
MA37407B1 (fr) 2018-03-30
PT2831113T (pt) 2018-06-20
MY184037A (en) 2021-03-17
JP2019050822A (ja) 2019-04-04
CY1121466T1 (el) 2020-05-29
EA201491784A1 (ru) 2015-02-27
MA37407A1 (fr) 2016-05-31
JP2024038036A (ja) 2024-03-19
CA2868353A1 (en) 2013-10-03
DK3246339T3 (da) 2020-01-27
CN104334578B (zh) 2021-10-08
DOP2014000199A (es) 2014-10-31
JP6779012B2 (ja) 2020-11-04
MX2014011688A (es) 2015-01-22
MY166157A (en) 2018-06-06

Similar Documents

Publication Publication Date Title
KR102035882B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
JP6696899B2 (ja) プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用
HK1206754B (en) Antibodies to bradykinin b1 receptor ligands
OA17139A (en) Antibodies to bradykinin B1 receptor ligands

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141017

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180315

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190412

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190718

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20191016

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191017

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191017

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220915

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230918

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240919

Start annual number: 6

End annual number: 6